Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, cilt.13, ss.1-13, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 13
- Basım Tarihi: 2022
- Doi Numarası: 10.1177/20420188221139650
- Dergi Adı: THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
- Sayfa Sayıları: ss.1-13
- Anahtar Kelimeler: diagnosis, epidemiology, fibrosis, metabolic (dysfunction)-associated fatty liver disease, nonalcoholic fatty liver disease, CONTROLLED ATTENUATION PARAMETER, NAFLD FIBROSIS SCORE, HEPATIC STEATOSIS, PRIMARY-CARE, OUTCOMES, INDEX, STEATOHEPATITIS, ELASTOGRAPHY, MANAGEMENT, MORTALITY
- Recep Tayyip Erdoğan Üniversitesi Adresli: Evet
Özet
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common
chronic liver disease worldwide – with an estimated global prevalence of 37%. Different from
nonalcoholic fatty liver disease (NAFLD), which is an exclusion diagnosis, MAFLD is defined
by a set of positive criteria. This recent change in terminology is challenging because MAFLD
and NAFLD denote two similar, albeit not identical, clinical populations. When the diagnostic
criteria for MAFLD are applied, liver histology appears more severe and clinical outcomes
are less favorable. However, the clinical management of MAFLD and NAFLD remains similar.
While liver biopsy is still the reference standard for achieving a final diagnosis, noninvasive
imaging- or biomarker-based diagnostic modalities are currently gaining momentum.
However, liver biopsy should be recommended when diagnostic challenges exist. In this
review, we compared the epidemiology, natural history, and diagnosis of MAFLD with respect
to the traditional NAFLD definition.